Kiora Pharmaceuticals, Inc. - Common Stock (KPRX)
3.1000
+0.0100 (0.32%)
NASDAQ · Last Trade: Jun 6th, 2:08 PM EDT

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · June 4, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · June 4, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 4, 2025

Via Benzinga · June 3, 2025
Via Benzinga · April 16, 2025

KPRX stock results show that Kiora Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024

Via Benzinga · June 6, 2024

KPRX stock results show that Kiora Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 10, 2024

Via Benzinga · April 24, 2024

Via Benzinga · April 24, 2024

We are starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to read about this morning!
Via InvestorPlace · April 24, 2024

Via Benzinga · April 23, 2024

Via Benzinga · March 7, 2024

Via Benzinga · February 9, 2024

Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.
Via Benzinga · February 2, 2024

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
Via Benzinga · February 2, 2024

Via Benzinga · February 2, 2024

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers worth keeping tabs on Friday!
Via InvestorPlace · February 2, 2024

Via Benzinga · February 1, 2024

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
Via Benzinga · February 1, 2024

Via Benzinga · February 1, 2024

Kiora Pharmaceuticals also entered into a securities purchase agreement with certain institutional investors, pursuant to which Kiora agreed to issue and sell 15,800,000 shares and warrants for expected aggregate gross proceeds at closing of approximately $15 million and potential future warrant exercise gross proceeds of approximately $30 million.
Via Benzinga · February 1, 2024